-- Surgery 2 Question Bank: Topic 60 - Transplant Surgery Basics (32 MCQs)
-- Category: Surgery 2 (a0000002-0000-0000-0000-000000000002)
-- Topic: Transplant Surgery Basics (c0000060-0000-0000-0000-000000000060)

INSERT INTO questions (topic_id, category_id, question_text, option_a, option_b, option_c, option_d, option_e, correct_option, explanation, difficulty, cognitive_level) VALUES
('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Organ transplantation involves transfer of organs between:', 'Same individual only', 'Different individuals (allograft) or same individual (autograft)', 'Different species only', 'Only identical twins', 'Artificial organs only', 'B', 'Transplant types: autograft (same individual), isograft (identical twin), allograft (same species, different individual), xenograft (different species). Allograft most common clinical transplant.', 'easy', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'The major histocompatibility complex (MHC) in humans is called:', 'ABO system', 'Human Leukocyte Antigen (HLA) system', 'Rh system', 'Complement system', 'Immunoglobulin system', 'B', 'HLA system: human MHC on chromosome 6. Class I (A, B, C) on all nucleated cells. Class II (DR, DQ, DP) on antigen-presenting cells. HLA matching improves outcomes, especially for kidney transplant.', 'easy', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'ABO blood group compatibility in transplantation is:', 'Not important', 'Essential for most solid organ transplants', 'Only for liver', 'Only for kidney', 'Never considered', 'B', 'ABO compatibility: essential for transplantation. ABO-incompatible transplant possible (desensitization protocols) but increases complexity and risk. Rh compatibility less critical (not expressed on solid organs).', 'easy', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Hyperacute rejection occurs:', 'Months after transplant', 'Within minutes to hours of transplantation', 'Years later', 'Only with chronic rejection', 'Never', 'B', 'Hyperacute rejection: preformed antibodies (against ABO or HLA) cause immediate graft destruction. Occurs on operating table. Prevention: crossmatch testing (detect preformed antibodies). Now rare.', 'easy', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Acute rejection typically occurs:', 'Immediately', 'Days to weeks after transplantation', 'Only years later', 'Before transplant', 'Never with immunosuppression', 'B', 'Acute rejection: T-cell mediated, occurs days to months (most common first 3-6 months). Cellular or antibody-mediated. Diagnosed by biopsy. Usually reversible with increased immunosuppression.', 'easy', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Chronic rejection is characterized by:', 'Rapid onset', 'Gradual progressive graft dysfunction over months to years', 'Immediate hyperacute response', 'Complete reversibility', 'Absence of immunological mechanisms', 'B', 'Chronic rejection: slow progressive dysfunction, fibrosis, vascular changes (chronic allograft vasculopathy). Multifactorial. Not readily reversible. Leading cause of late graft loss. Chronic allograft nephropathy.', 'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'The mainstay of immunosuppression in solid organ transplantation includes:', 'Antibiotics only', 'Calcineurin inhibitors (tacrolimus/cyclosporine), antimetabolites, and steroids', 'Chemotherapy only', 'Radiation only', 'No medication needed', 'B', 'Triple immunosuppression: calcineurin inhibitor (tacrolimus/cyclosporine), antimetabolite (mycophenolate/azathioprine), corticosteroid. Induction agents for high-risk (antithymocyte globulin, basiliximab).', 'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Tacrolimus (FK506) acts by:', 'Blocking DNA synthesis', 'Inhibiting calcineurin and IL-2 production', 'Killing T-cells directly', 'Blocking B-cells only', 'Enhancing immune response', 'B', 'Tacrolimus: calcineurin inhibitor, blocks IL-2 transcription and T-cell activation. More potent than cyclosporine. Side effects: nephrotoxicity, neurotoxicity, diabetes, hypertension. Monitor trough levels.', 'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Major side effects of calcineurin inhibitors include:', 'No side effects', 'Nephrotoxicity, neurotoxicity, hypertension, and diabetes', 'Only skin rash', 'Weight loss', 'Immunostimulation', 'B', 'CNI toxicity: nephrotoxicity (acute and chronic), hypertension, diabetes (tacrolimus > cyclosporine), tremor, neurotoxicity, electrolyte abnormalities. Narrow therapeutic window. Level monitoring essential.', 'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Long-term risks of immunosuppression include:', 'No long-term risks', 'Infection, malignancy, cardiovascular disease, and metabolic complications', 'Improved immunity', 'Better wound healing', 'Decreased cancer risk', 'B', 'Immunosuppression complications: increased infection (opportunistic, viral), malignancy (skin cancer, PTLD, other), cardiovascular (diabetes, hypertension, dyslipidemia), metabolic bone disease, nephrotoxicity.', 'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Post-transplant lymphoproliferative disorder (PTLD) is:', 'Autoimmune disease', 'EBV-associated lymphoma-like condition in immunosuppressed patients', 'Normal response', 'Rejection type', 'Infection only', 'B', 'PTLD: spectrum from polyclonal lymphoid proliferation to lymphoma. EBV-driven (primary EBV infection in transplant). Risk: intensity of immunosuppression. Treatment: reduce immunosuppression, rituximab, chemotherapy.', 'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Deceased donor organs may be retrieved from:', 'Any deceased person', 'Brain-dead or cardiac death donors meeting criteria', 'Only relatives', 'Only young donors', 'Anytime after death', 'B', 'Deceased donation: donation after brain death (DBD) or donation after circulatory death (DCD). Requires consent, absence of contraindications (certain infections, malignancies). Allocation by established criteria.', 'easy', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Brain death is characterized by:', 'Coma only', 'Irreversible cessation of all brain function including brainstem', 'Only EEG silence', 'Only loss of consciousness', 'Temporary condition', 'B', 'Brain death criteria: coma with known cause, absent brainstem reflexes (pupillary, corneal, oculocephalic, oculovestibular, gag, cough), absent respiratory drive (apnoea test). May need confirmatory testing.', 'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Living kidney donation:', 'Is never performed', 'Is safe with minimal long-term risk to donor', 'Is illegal', 'Causes kidney failure in donor', 'Requires immunosuppression in donor', 'B', 'Living kidney donation: excellent option. Minimal long-term risk to donor (slight increase in ESRD risk but absolute risk remains low). Better outcomes than deceased donor. Thorough donor evaluation essential.', 'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'The most commonly transplanted solid organ worldwide is:', 'Heart', 'Kidney', 'Liver', 'Lung', 'Pancreas', 'B', 'Kidney transplant: most common solid organ transplant. Dialysis provides bridge for ESRD patients. Living donor option. Excellent outcomes (>95% 1-year graft survival). Placed in iliac fossa (heterotopic).', 'easy', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Kidney transplant is the treatment of choice for ESRD because:', 'Dialysis is unavailable', 'It provides better quality of life and survival than dialysis', 'It is cheaper always', 'It is simpler', 'It never fails', 'B', 'Transplant vs dialysis: kidney transplant offers better survival, quality of life, freedom from dialysis schedule, cost-effective long-term. Pre-emptive transplant (before dialysis) optimal when possible.', 'easy', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Kidney transplant is typically placed:', 'In the original kidney location', 'In the iliac fossa (heterotopic)', 'In the thorax', 'Subcutaneously', 'In the thigh', 'B', 'Kidney placement: iliac fossa (heterotopic), anastomosed to iliac vessels. Native kidneys usually left in place. Ureter implanted into bladder. More accessible for biopsy/intervention.', 'easy', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Delayed graft function after kidney transplant is more common with:', 'Living donor kidneys', 'Deceased donor kidneys (especially DCD)', 'Young donor kidneys', 'Short cold ischemia time', 'HLA-identical donors', 'B', 'Delayed graft function: need for dialysis in first week. More common: DCD donors, prolonged cold ischemia, donor factors (age, comorbidities). Usually recovers but associated with worse long-term outcomes.', 'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Liver transplant is uniquely characterized by:', 'No immunosuppression needed', 'The ability to accept ABO-compatible but not HLA-matched organs', 'Need for perfect HLA match', 'No rejection ever', 'Only deceased donors', 'B', 'Liver transplant: HLA matching not required (liver is immunologically privileged). ABO compatibility important. Can regenerate (allows living donor with right lobe). MELD score for deceased donor allocation.', 'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'The MELD score is used for:', 'Kidney allocation', 'Liver transplant prioritization based on disease severity', 'Heart allocation', 'Lung allocation', 'All organ allocation', 'B', 'MELD (Model for End-stage Liver Disease): bilirubin, INR, creatinine. Predicts 3-month mortality in liver disease. Used for deceased donor liver allocation - sickest patients prioritized. Exception points for some conditions.', 'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Indications for liver transplant include:', 'All liver disease', 'Acute liver failure, decompensated cirrhosis, and hepatocellular carcinoma within criteria', 'Only viral hepatitis', 'Only alcoholic liver disease', 'Only tumours', 'B', 'Liver transplant indications: acute liver failure (Kings College criteria), decompensated cirrhosis (any aetiology), HCC within Milan criteria (single ≤5cm or up to 3 ≤3cm each), metabolic diseases.', 'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Heart transplant is indicated for:', 'All heart failure', 'End-stage heart failure refractory to maximal medical therapy', 'Mild heart failure', 'Stable angina', 'Hypertension', 'B', 'Heart transplant: end-stage heart failure (NYHA III-IV), refractory to medications, no other options (high surgical risk, failed devices). Mechanical circulatory support (LVAD) as bridge or destination therapy.', 'easy', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'The major limitation of heart transplantation is:', 'Surgical technique', 'Shortage of donor organs', 'Rejection never occurs', 'Too many donors', 'Perfect outcomes', 'B', 'Heart transplant limitation: severe donor shortage. Many patients die waiting. Careful allocation essential. Mechanical support (LVAD) extends survival on waiting list. Median survival post-transplant >10 years.', 'easy', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Lung transplant may be performed as:', 'Only bilateral', 'Single or bilateral lung transplant', 'Only combined heart-lung', 'Never performed', 'Only right lung', 'B', 'Lung transplant: single or bilateral. Bilateral for CF, bronchiectasis, pulmonary hypertension. Single may be appropriate for COPD, fibrosis. Shortest waiting time of solid organs but limited donor availability.', 'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Major long-term complication of lung transplant is:', 'No complications', 'Chronic lung allograft dysfunction (bronchiolitis obliterans syndrome)', 'Improved lung function', 'Rejection never occurs', 'Weight loss only', 'B', 'Bronchiolitis obliterans syndrome (BOS): form of chronic rejection in lung transplant. Progressive airflow limitation. Leading cause of death after first year. Prevention/treatment challenging.', 'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Pancreas transplant is primarily performed for:', 'Pancreatitis', 'Type 1 diabetes mellitus (often with kidney transplant)', 'Type 2 diabetes', 'Pancreatic cancer', 'Cystic fibrosis', 'B', 'Pancreas transplant: for type 1 DM. Often simultaneous pancreas-kidney (SPK) for diabetic ESRD. Pancreas alone or after kidney (PAK, PKA) options. Achieves insulin independence, prevents/reverses complications.', 'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Cold ischemia time refers to:', 'Time during surgery', 'Time organ is preserved outside body on ice', 'Time after implantation', 'Time on waiting list', 'Time in ICU', 'B', 'Cold ischemia time: period from cold perfusion in donor to reperfusion in recipient. Minimized to reduce ischemia-reperfusion injury. Limits: kidney 24-36h, liver 12-18h, heart/lung 4-6h. Affects outcomes.', 'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Preservation solutions for organ transplant include:', 'Normal saline only', 'University of Wisconsin (UW), HTK, and other specialized solutions', 'Distilled water', 'Blood only', 'Alcohol', 'B', 'Preservation solutions: UW solution (gold standard), HTK (Custodiol), Celsior. Contain impermeants, antioxidants, buffers. Reduce cellular swelling, prevent damage. Machine perfusion increasingly used.', 'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'CMV (cytomegalovirus) infection in transplant recipients:', 'Never occurs', 'Is a major infectious complication requiring prophylaxis or preemptive therapy', 'Is beneficial', 'Indicates rejection', 'Requires no treatment', 'B', 'CMV in transplant: major opportunistic infection. D+/R- (donor positive, recipient negative) highest risk. Prophylaxis or preemptive monitoring strategy. Can cause tissue-invasive disease. Valganciclovir treatment.', 'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Xenotransplantation refers to:', 'Human to human', 'Transplantation between different species', 'Artificial organs', 'Autotransplantation', 'Twin transplantation', 'B', 'Xenotransplantation: organs from different species (typically pig to human). Research ongoing - genetic modification to prevent hyperacute rejection. Potential to address donor shortage. Ethical considerations.', 'easy', 'knowledge'),

('c0000060-0000-0000-0000-000000000060'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Ethical principles in organ allocation include:', 'First come first served only', 'Equity, utility, and urgency balanced with medical criteria', 'Highest bidder', 'Age only', 'Random selection', 'B', 'Organ allocation ethics: balance equity (fair access), utility (best outcomes), and urgency. Medical criteria for listing and matching. National allocation systems. Avoid discrimination. Transparency important.', 'medium', 'knowledge');
